Malignant neoplasm of upper lobe, right bronchus or lung
ICD-10 C34.11 is a billable code used to indicate a diagnosis of malignant neoplasm of upper lobe, right bronchus or lung.
C34.11 refers to a malignant neoplasm located in the upper lobe of the right bronchus or lung. This diagnosis is commonly associated with lung cancer, which is characterized by uncontrolled cell growth in lung tissues. The primary risk factor for lung cancer is a history of smoking, with both active and passive exposure contributing significantly to the disease's development. Staging of lung cancer is crucial for determining treatment options and prognosis, typically classified using the TNM system, which assesses tumor size (T), lymph node involvement (N), and metastasis (M). Molecular markers, such as EGFR mutations and ALK rearrangements, play a vital role in personalizing treatment, guiding the use of targeted therapies. Treatment algorithms often include a combination of surgery, chemotherapy, radiation therapy, and immunotherapy, depending on the stage and specific characteristics of the tumor. Accurate coding for C34.11 requires comprehensive documentation of the patient's smoking history, staging details, and any molecular testing results to ensure appropriate treatment and reimbursement.
Detailed pathology reports, imaging studies, and treatment plans.
Initial diagnosis of lung cancer, staging workup, and treatment planning.
Ensure all molecular testing results are documented to support targeted therapy coding.
Pulmonary function tests, imaging, and smoking history.
Evaluation of lung nodules, management of lung cancer patients, and follow-up care.
Document any respiratory symptoms and their relation to the malignancy.
Used for surgical resection of the right upper lobe tumor.
Operative report detailing the procedure and findings.
Oncology and thoracic surgery documentation must align with coding.
Molecular markers are crucial for determining targeted therapies and must be documented to support the coding of lung cancer accurately. They influence treatment decisions and can impact reimbursement.
